# Kelun Botai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kelun-botai

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.kelun-biotech.com
- Total disclosed funding: $193M
- Latest round: Series B (Dec 29, 2022)
- Investors on record: 10

## About

Established in 2016 and based in Chengdu, China, Kelun Botai is a biopharmaceutical company that focuses on the research and development, production, and sales of molecular biology medical drugs. Kelun Botai's parent company is a publicly traded pharmaceutical group, Sichuan Kelun Pharmaceutical Co., Ltd. In 2022, it established cooperation with Merck Sharp & Dohme LLC, got 9 authorized drugs cooperation, and the total amount reached USD 11 billion. In July 2023, it was listed on the Hongkong Stock Exchange with stock code 6990. The Chairman of the Board, Gexin Liu, graduated from Dalian University and he served as a director of Kelun Research Institute from November 2020 to October 2022.

The company's business is the research and development, production, and distribution of small molecular drugs. It used the technologies of antibody-drug conjugates (ADC), bispecific monoclonal antibodies (BMA), and new targets. It has 33 drug programs, used for the treatment of tumors, inflammation, and metabolic diseases such as breast cancer, stomach cancer, lung cancer, etc. It includes 14 drug programs in clinical trials in China, and 3 programs performed in clinical trials in the USA.

The company's operating revenue in 2022 is CNY 8.039 million.

## Funding rounds

- Series B, Dec 29, 2022, $193M — IDG Capital, Merck & Co., Inc., CS Capital, Sherpa Healthcare Partners, Geuniom Group, BOSC International, Zhumei Investment, Shenzhen Yunqi Private Equity Investment Fund Management, Chengdu Longyi Technology Co., Ltd., Cinda Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Merck & Co., Inc. — Series B
- CS Capital — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- Geuniom Group — Series B
- BOSC International (https://capitalatlas.ai/funds/bosc-international) — Series B
- Zhumei Investment — Series B
- Shenzhen Yunqi Private Equity Investment Fund Management — Series B
- Chengdu Longyi Technology Co., Ltd. — Series B
- Cinda Capital (https://capitalatlas.ai/funds/cinda-capital) — Series B